Compare Regeneron Pharmaceuticals Inc (REGN) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Ryanair Holdings plc trades at $58.52 (market cap $29.69B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays the higher dividend (1.68%). Which is the better fit depends on your goals.
| REGN | RYAAY | |
|---|---|---|
Market Cap | $70.79B | $29.69B |
Sector | Health | Industrials |
52-Week High | $812.27 | $73.82 |
52-Week Low | $545.46 | $53.24 |
Enterprise Value | $64.74B | $26.70B |
Dividend Yield | 0.56% | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
RYAAY trades at $58.80, down 6.03% amid a bearish technical signal. Recent Q1 2027 earnings missed expectations due to lower fares and higher fuel costs, though the company maintains strong profitability with a 13.98% net margin. Analyst consensus remains positive with 62.5% buy ratings, citing long-term advantages despite near-term headwinds from geopolitical tensions and industry volatility.
The outlook is cautious short-term given earnings pressure and technical weakness, but the strong balance sheet and potential industry consolidation offer recovery potential. Key risks include fuel price volatility and competitive fare pressures, while institutional sentiment suggests the sell-off may be overdone for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
